<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2904210705
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OCTAGAM 100 mg/ml solution for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NORMAL HUMAN IMMUNOGLOBULIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4482.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OCTAPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OCTAPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 521]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Faisal Musaed El Seif Saudi Pharmaceutical Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OCTAPHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J06BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Octagam 10% is a human normal immunoglobulin (IgG) solution (i.e. solution of human antibodies) for intravenous administration (i.e. infusion into a vein). Immunoglobulins are normal constituents of the human body and support the immune defence of your body. Octagam 10% contains all IgG activities which are present in the normal population. Adequate doses of this medicinal product may restore abnormally low IgG levels to the normal range.</p><p>Octagam 10% has a broad spectrum of antibodies against various infectious agents.</p><p><strong>&nbsp;</strong></p><p><strong>What Octagam </strong><strong>10% is used for:</strong></p><p>Octagam 10% is used</p><p>* as replacement therapy in patients who do not have sufficient amounts of own antibodies.</p><p>* in certain inflammatory diseases</p><p>* to prevent or treat infections after a bone marrow transplantation</p><p>&nbsp;</p><p>Octagam 10% is used as replacement therapy. There are 3 groups of replacement therapy:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with inborn deficiency of antibodies (primary immunodeficiency syndromes: congenital agammaglobulinaemia and hypogamma&shy;globulinaemia, common variable immunodeficiency, severe combined immuno&shy;deficiencies, Wiskott Aldrich syndrome)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with diseases of the blood that lead to a lack of antibodies and to recurrent infections (Myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children with congenital AIDS who have repeated bacterial infections</p><p>&nbsp;</p><p>Octagam 10% can be used in the following inflammatory diseases:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In adults or children who do not have a sufficient number of platelets (idiopathic thrombocytopenic purpura) and who have a high risk of bleeding or prior to surgery to correct the platelet count</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with a disease that leads to inflammation of various organs (Kawasaki disease)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with a disease that can lead to inflammation of certain parts of the nervous system (Guillain Barr&eacute; syndrome)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Octagam 10%</strong><strong>:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to human immunoglobulin or any of the other ingredients contained in Octagam 10%.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a deficiency of immunoglobulin A (IgA deficiency) with anti-IgA antibodies.</p><p><strong>Take special care with Octagam 10%</strong><strong>:</strong></p><p>Tell your doctor if you have any other illnesses.</p><p>In the case of an adverse reaction, either the rate of administration must be reduced or the infusion must be stopped. The treatment of the adverse event required will depend on the nature and severity of the side effect.</p><p><u>Virus safety</u></p><p>When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; testing of each donation and pools of plasma for signs of virus/infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; steps included by the manufacturers in the processing of the blood or plasma that can inactivate or remove viruses.</p><p>Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.</p><p>The measures taken are considered effective for encapsulated viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus.</p><p>The measures taken may be of limited value against non-encapsulated viruses such as hepatitis A virus and parvovirus B19.</p><p>Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective.</p><p><strong>&nbsp;</strong></p><p>It is strongly recommended that every time you receive a dose of Octagam 10% the name and batch number of the product are recorded in order to maintain a record of the batches used.</p><p><strong>Using other medicines:</strong></p><p>The infusion line may be flushed before and after administration of Octagam 10% with either normal saline or 5% dextrose in water.</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, or if you have received a vaccination in the last three months.</p><p>Octagam 10% may impair the effect of live attenuated virus vaccines such as measles, rubella, mumps and varicella.</p><p>After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year.</p><p>Inform your doctor that you are taking immunoglobulin when you give a blood sample, as this treatment may affect the results.</p><p>&nbsp;</p><p><u>Blood Glucose Testing</u></p><p>Some types of blood glucose testing systems (so called glucometers) falsely interpret the maltose contained in Octagam 10% as glucose. This may result in falsely elevated glucose readings <strong>during an infusion and</strong> for a period of about 15 hours after the end of the infusion and, consequently, in the inappropriate administration of insulin, resulting in life-threatening hypoglycaemia (i.e. a decreased blood sugar level).</p><p>Also, cases of true hypoglycaemia may go untreated if the hypoglycaemic state is masked by falsely elevated glucose readings.</p><p><strong>Accordingly, when administering Octagam </strong><strong>10% or other maltose-containing products, the measurement of blood glucose must be done with a test-system using a glucose-specific method. Systems based on the </strong><strong>glucose dehydrogenase pyrroloquinolinequinone (GDH PQQ) or </strong><strong>glucose-dye-oxidoreductase methods should not be used.</strong></p><p>Review carefully the product information of the blood glucose testing system, including that of the test strips, to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, please ask your treating physician to determine if the glucose testing system you are using is appropriate for use with maltose-containing parenteral products.</p><p><strong>Pregnancy and breast-feeding:</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.</p><p>Immunoglobulins are excreted into the milk and may contribute to the transfer of protective antibodies to the newborn.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines:</strong></p><p>There are no indications that immunoglobulin preparations may impair the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will decide if you need Octagam 10% and at what dose. Octagam 10% is administered as an intravenous infusion (infusion into a vein) by healthcare personnel. The dose and dosage regimen is dependant on the indication and may need to be individualised for each patient.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Octagam 10% can cause side effects, although not everybody gets them.</p><p><u>Adverse reactions which may occur occasionally:</u></p><p>Chills, headache, fever, vomiting, allergic reactions, nausea, joint pain, changes in blood pressure (low/high blood pressure) and moderate low back pain</p><p><u>Adverse reactions which may occur rarely and in isolated cases:</u></p><p>Human normal immunoglobulins may cause a fall in blood pressure and an anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.</p><p><u>The following cases, isolated cases and rare cases have been observed with human normal immunoglobulin:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible aseptic meningitis (inflammation of the tissue surrounding the brain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible haemolytic anaemia/haemolysis (destruction of red blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transient increases in liver transaminases (blood markers that indicate temporarily impaired liver function)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; regressive cutaneous reactions (reactions of the skin), often eczema-like</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in creatinine (blood marker that indicates impaired function of the kidneys) and/or acute renal failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombotic events (formation of blood clots) have been reported</p><p>o&nbsp;&nbsp; in elderly patients</p><p>o&nbsp;&nbsp; in patients with signs of cerebral or cardiac ischemia (impaired blood circulation in the brain or heart vessels)</p><p>o&nbsp;&nbsp; in overweight and overly volume depleted patients</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you experience any of the symptoms above, contact your doctor as soon as possible.</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&ndash;<strong><em>&ndash; Saudi Arabia:</em></strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&ndash;&ndash; Fax: +966-11-205-7662</p><p>&ndash;&ndash; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>&ndash;&ndash; Toll free phone: 8002490000</p><p>&ndash;&ndash; E-mail: npc.drug@sfda.gov.sa</p><p>&ndash;&ndash; Website: www.sfda.gov.sa/npc</p><p>&ndash;<strong><em>&ndash; Other GCC States:</em></strong></p><p>&ndash;&ndash; Please contact the relevant competent authority</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use Octagam 10% after the expiry date which is stated on the label and the carton.</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Keep the container in the outer carton in order to protect from light. Do not freeze.</p><p>The product may be removed from the refrigerator for a single period of up to 9 months (without exceeding the expiry date) and stored at a temperature below 25&deg;C. At the end of this period, the product should not be refrigerated again and should be disposed of. The date at which the product was taken out of the refrigerator should be recorded on the outer carton.</p><p>Do not use Octagam 10% if you notice that the solution is cloudy, has deposits or is coloured intensively.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is human normal immunoglobulin 10% (at least 95% is immunoglobulin G).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are maltose and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Octagam 10% is a solution for infusion and is available in vial (2g/20ml) or bottles (5g/50ml, 10g/100ml, 20g/200ml). Pack size of 1.
The solution is clear or slightly opalescent, colourless or slightly yellow. 
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Octapharma AG</p><p>Seidenstrasse 2</p><p>CH-8853 Lachen</p><p>Switzerland</p><p>Tel: +41 5545 121 0</p><p><strong>Manufacturer:</strong></p><p>Octapharma Pharmazeutika Produktionsges.m.b.H.</p><p>Oberlaaer Strasse 235, A-1100 Vienna, Austria</p><p>Tel: +43 1 61032 0<br />Fax: +43 1 61032 9300</p><p>&nbsp;</p><p>Octapharma AB</p><p>SE-112 75 Stockholm</p><p>Sweden</p><p>Tel: +46 8 566 43 000</p><p>&nbsp;</p><p>Octapharma S.A<em>.</em>S.</p><p>70-72 rue de Mar&egrave;chal Foch, BP 33, F-67380 Lingolsheim, France</p><p>Tel: +33 3 88 78 89 89</p><p>Fax +33 3 88 78 89 78</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>طبيعة عقار أوكتاجام </strong><strong>10</strong>%<strong>:</strong></p><p dir="RTL">يتم تناول عقار أوكتاجام 10<strong>%</strong> الذي هو عبارة عن محلول للجلوبيولين المناعي الطبيعي للإنسان (النوع G) يتم الحقن في الوريد (كمحاليل الأجسام المضادة التي يستخدمها الإنسان). الجلوبيولينات المناعية هي مقومات طبيعية للجسم البشري، يتم استخدامها لدعم الدفاع المناعي للجسم. يحتوي أوكتاجام 10<strong>%</strong> على منشطات للجلوبيولين المناعي الطبيعي (النوع G) الموجود بالفعل في أجسام البشر الطبيعيين. تناول الجرعات المناسبة من هذا المنتج العلاجي قد يؤدي إلى إعادة مستويات الجلوبيولين المناعي (النوع G) المنخفض إلى مستواه الطبيعي.</p><p dir="RTL">يحتوي أوكتاجام 10<strong>%</strong> على مجموعة كبيرة من الأجسام المضادة التي تعمل ضد العديد من العوامل المسببة للعدوى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>دواعي استخدام عقار أوكتاجام </strong><strong>10</strong>%<strong>:</strong></p><p dir="RTL">يتم استخدام عقار أوكتاجام 10<strong>%</strong></p><p dir="RTL">* كعلاج بديل للمرضى الذين يعانون من نقص في كميات الأجسام المضادة الذاتية.</p><p dir="RTL">* مع بعض الأمراض الالتهابية</p><p dir="RTL">* للوقاية من العدوى أو للعلاج منها بعد إجراء عمليات زرع نُـقي النخاع العظمي</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم أوكتاجام 10<strong>% </strong>كعلاج بديل. هناك ثلاث مجموعات من العلاجات البديلة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بنقص فطري في الأجسام المضادة (المتلازمات الأولية لنقص المناعة: نقص فطري في جلوبيولينات جاما، ونقص جلوبيولينات جاما، والنقص المناعي المتغير الشائع، والنقص المناعي المركب الحاد، ومتلازمة ويسكوت ألدريش)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يعانون من أمراض الدم التي تؤدي إلى نقص في الأجسام المضادة وتكرار حالات العدوى (ابيضاض الدم الليمفاوي المزمن أو الذي يصاحبه ورم نقوي مع نقص جلوبيولينات جاما الحاد الثانوي وحالات العدوى المتكررة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال الذين يعانون من متلازمة نقص المناعة المكتسبة وتكررت لديهم حالات العدوى البكتيرية</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام أوكتاجام 10<strong>% </strong>مع الأمراض الالتهابية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع البالغين أو الأطفال الذين يعانون من نقص في عدد الصفائح الدموية (الفُرْفُرِيَّةُ قَليلَةُ الصُّفَيحاتِ مَجْهولَةُ السَّبَب)، أو الذين يتعرضون لمخاطر كبيرة جراء النزف، أو قبل إجراء عملية جراحية لتصحيح عدد الصفائح الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع المرضى الذين يعانون من مرض ما يؤدي إلى التهاب العديد من الأعضاء (مرض كاواساكي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع المرضى الذين يعانون من مرض يمكن أن يتسبب في التهاب أجزاء بعينها في النظام العصبي (متلازمة غيلان باريه)</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم أوكتاجام <strong>10</strong>%:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية من الجلوبيولين المناعي البشري أو أي من المكونات التي يتكون منها أوكتاجام 10<strong>%</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص في الجلوبيولين المناعي من النوع A مع وجود أجسام مضادة لمستضدات الجلوبيولين المناعي من النوع A.</p><p dir="RTL">انتبه وتوخَّ الحذر عند استخدام أوكتاجام <strong>10</strong>%:</p><p dir="RTL"><strong>قم بإخبار طبيبك في حال إصابتك بأي أمراض أخرى.</strong></p><p dir="RTL">في حال التعرض لأي رد فعل عكسي، أو وجوب تقليل الجرعة التي تتناولها، أو إيقاف الحقن الوريدي. سيتوقف العلاج المطلوب لهذا الحدث العكسي وفقًا لطبيعة العرض الجانبي وشدته.</p><p dir="RTL"><strong><u>السلامة من انتقال الفيروس</u></strong></p><p dir="RTL">عند صناعة الأدوية من دم أو بلازما كائن بشري، تكون هناك مقاييس يتعين الالتزام بها للوقاية من العدوى التي يتم انتقالها إلى المرضى. وهذا يتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاختيار الدقيق لمتبرعي الدم والبلازما بحيث يتم التأكد من عدم وجود أي مخاطر من حمل العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار كل عملية تبرع وأحواض البلازما لتفقد أي علامات لفيروس/عدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخطوات التي تدرجها المصانع في عملية معالجة الدم أو البلازما، والتي بإمكانها أن تثبط من عمل الفيروس أو التخلص منه.</p><p dir="RTL">بخلاف هذه المقاييس، عند تناول الأدوية المعدَّة من دم أو بلازما بشرية، لا يمكن استبعاد إمكانية نقل العدوى تمامًا. وينطبق هذا أيضًا على أي فيروسات غير معروفة أو ناشئة، أو أي أنواع أخرى من العدوى.</p><p dir="RTL">تعد المقاييس التي تم تسجيلها ذات فعالية بالنسبة للفيروسات الممحفظة، والتي تتضح على سبيل المثال في فيروس نقص المناعة المكتسبة البشري (الإيدز)، وفيروس الالتهاب الكبدي الوبائي B، وفيروس الالتهاب الكبدي الوبائي C.</p><p dir="RTL">قد تكون المقاييس المأخوذة عبارة عن قيمة محدودة مضادة للفيروسات الغير محاطة، والتي تتضح على سبيل المثال في فيروس الالتهاب الكبدي الوبائي A والفيروس بارفو فيروس B19.</p><p dir="RTL">ربما لا يرتبط الجلوبيولين المناعي في حالات العدوى بفيروس الالتهاب الكبدي الوبائي A أو البايرو فيروس B19 نظرًا لأن الأجسام المضادة الموجودة في هذا المنتج والتي يسير اتجاه عملها ضد هذه الحالات من العدوى تكون أجسامًا وقائية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ينصح بشدة بتسجيل الاسم ورقم تشغيلة المنتج في كل مرة يتم فيها تناول جرعة من أوكتاجام 10<strong> % </strong>&nbsp;وذلك للمحافظة على وجود سجل يضم التشغيلات المستخدمة.</p><p dir="RTL"><strong>استخدام أدوية أخرى:</strong></p><p dir="RTL">قد يتدفق خط الحقن بغزارة قبل وبعد تناول أوكتاجام 10<strong>%</strong> سواء كان ذلك مع محلول ملحي عادي أو في حال وجود 5% من الدكستروز في الماء.</p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى أو كنت قد تناولت مؤخرًا أيًا منها، بما في ذلك الأدوية التي يتم الحصول عليها دون وصف طبيب، أو في حال التلقيح خلال الأشهر الثلاث الأخيرة.</p><p dir="RTL">قد يضعف أوكتاجام 10<strong>% </strong>تأثير لقاح الفيروس المضعف والذي يتضح على سبيل المثال في مرض الحصبة، والحصبة الألمانية، وفيروس النُّكاف، والحماق.</p><p dir="RTL">بعد تناول هذا المنتج، يجب أن تمر فترة فاصلة قدرها ثلاثة أشهر قبل التلقيح بلقاح الفيروسات المضعفة. في حال الإصابة بالحصبة، قد يستمر هذا العجز لفترة تصل إلى عام كامل.</p><p dir="RTL">أبلِغ طبيبك بأنك تتناول الجلوبيولين المناعي عند ترك عينة من الدم، وذلك لأن هذا العلاج قد يؤثر على النتائج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>اختبار جلوكوز الدم</u></p><p dir="RTL">بعض أنظمة اختبار جلوكوز الدم (التي يطلق عليها أجهزة قياس نسبة السكر) ترى المالتوز الموجود في أوكتاجام 10<strong>%</strong> على أنه جلوكوز. قد يؤدي هذا إلى ظهور نتائج خاطئة في قراءات الجلوكوز الناتجة <strong>أثناء التقطير </strong>وذلك حتى فترة 15 ساعة بعد <em>الحقن</em> وبناء عليه يترتب تناول جرعة غير مناسبة من الإنسولين؛ الأمر الذي قد يهدد بالإصابة بمرض نقص السكر في الدم (على سبيل المثال: انخفاض مستوى السكر في الدم).</p><p dir="RTL">هذا بالإضافة إلى أن الانخفاض الفعلي في مستوى السكر في الدم قد يصعب الشفاء منه إذا تم تضليل حالة مرض نقص السكر في الدم بقراءات جلوكوز غير صحيحة.</p><p dir="RTL"><strong>وبناء على ذلك، عند تناول أوكتاجام </strong><strong>10</strong>% <strong>أو أي منتجات أخرى تحتوى على المالتوز، يجب أن يتم قياس جلوكوز الدم بنظام اختبار يعتمد على استخدام أداة من شأنها تحديد عنصر الجلوكوز. لا يجب استخدام<em> الأنظمة التي تعتمد على الوسائل النازعة لهيدروجين الجلوكوز </em></strong><strong><em>كالبايرولوكينولين كينون </em></strong><em>و<strong>جلوكوز داي أوكسيدوريدوكتاز.</strong></em></p><p dir="RTL">راجع بدقة معلومات المنتج الخاصة بنظام اختبار الجلوكوز في الدم، بما في ذلك شرائط الاختبار، وذلك من أجل تحديد ما إذا كان النظام مناسبًا للاستخدام عند تناول أي من المنتجات التي يتم حقنها وتحتوي على المالتوز. إذا كان هناك أي شك، فيُرجى مراجعة الطبيب المعالج لتحديد ما إذا كان نطام اختبار الجلوكوز الخاص بك مناسبًا للاستخدام في حال تناول أي منتجات حقن تحتوى على المالتوز أو غير مناسب.</p><p dir="RTL"><strong>بالنسبة للحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">راجع الطبيب أو الصيدلي للحصول على النصائح اللازمة قبل تناول الدواء.</p><p dir="RTL">لم يتم إجراء اختبارات للتأكد من سلامة هذا المنتج العلاجي على السيدات الحوامل في الاختبارات السريرية الخاضعة للمراقبة، ومن ثم ينبغي تناول هذا العقار بحذر شديد مع السيدات الحوامل والأمهات المرضعات. تنم التجارب السريرية المتعلقة بالجلوبيولين المناعي بأنه من غير المتوقع التعرض لأي آثار ضارة أثناء فترة الحمل على الأم، أو الجنين والأطفال حديثي الولادة.</p><p dir="RTL">يتم إفراز الجلوبيولين المناعي في لبن الأم، الأمر الذي يساهم في نقل الأجسام المضادة الوقائية إلى الأطفال حديثي الولادة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">لا توجد أي مؤشرات توضح أن مستحضرات الجليوبيولين المناعي قد تعيق القدرة على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقرر طبيبك الخاص ما إذا كنت بحاجة لتناول أوكتاجام 10<strong>% </strong>&nbsp;وكذلك الجرعة اللازمة. يتم تناول عقار أوكتاجام 10<strong>%</strong> من خلال الحقن في الوريد تحت اشراف طبي. يعتمد كل من الجرعة ونظامها على المؤشرات، وقد تختلف حاجة كل مريض للجرعة عن غيره.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك مزيد من الاستفسارات حول استخدام المنتج، فاسأل طبيبك الخاص أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل أي دواء، قد يتسبب أوكتاجام 10<strong>% </strong>في التعرض لأعراض جانبية على الرغم من أنها غير لازمة الحدوث بالنسبة لجميع الأفراد الذين يتعاطونه.</p><p dir="RTL"><u>ردود الأفعال العكسية التي قد تحدث أحيانًا:</u></p><p dir="RTL">قشعريرة، أو صداع، أو حرارة، أو تقيؤ، أو حساسية، أو غثيان، أو آلام في المفاصل، أو تغيرات في ضغط الدم (ضغط دم منخفض/مرتفع)، أو ألم معتدل في أسفل الظهر</p><p dir="RTL"><u>نادرًا ما تحدث ردود الفعل العكسية وفي حالات استثنائية:</u></p><p dir="RTL">قد تتسبب الجلوبيولينات المناعية الطبيعية في الإنسان إلى انخفاض في ضغط الدم، بالإضافة إلى التعرض لصدمة تَأَقِيَّة حتى إن لم يظهر أي فرط تحسس على المريض مقابل أي تناول مسبق للعقار.</p><p dir="RTL"><u>تمت ملاحظة الحالات التالية، والحالات الاستثنائية، والحالات النادرة التالي ذكرها مع الجلوبيولين المناعي الطبيعي في الإنسان:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب السحايا العقيم العكسي (التهاب النسيج المحيط بالمخ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف كريات الدم الحموقيء/انحلال الدم العكسي (تكسير خلايا الدم الحمراء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادات عابرة ناقلات الأمين الخاصة بالكبد (علامات دموية تشير إلى خلل مؤقت في وظائف الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسسات جلدية تراجعية (حكة جلدية)، غالبًا ما تشبه الإكزيما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الكرياتينين (علامات دموية تشير إلى خلل في وظائف الكلى) و/أو فشل كلوي حاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إثبات وجود لأحداث تخثرية (تكوينات لجلطات دموية)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المرضى المسنين</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المرضى الذين يعانون من علامات إقفار دماغي أو قلبي (إعاقة الدورة الدموية في أوعية المخ أو القلب)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع المرضى أصحاب الوزن الزائد، والذين يخسرون أحجامهم بشكل مفرط</p><p dir="RTL">إذا تطور أي من الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية بخلاف المدرجة في هذه النشرة، فيُرجى إبلاغ الطبيب أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية فتحدث إلى طبيبك أو الصيدلي. هذا يشمل أية آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكنك من خلال الإبلاغ عن الآثار الجانبية المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المملكة العربية السعودية</strong></p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: + (966-11) 2057662</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 800-249-0000</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: + (966-11) 2038222 ، فرعي: 2340-2334-2354-2353-2356-2317</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p dir="RTL"><strong>في بلدان مجلس التعاون الخليجي الأخرى</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية المختصة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب الاحتفاظ به بعيدًا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم أوكتاجام 10<strong>%</strong> بعد انتهاء مدة صلاحيته المدونة على ملصق المنتج وعلبته الكرتونية.</p><p dir="RTL">يتم حفظه في الثلاجة عند درجة حرارة (2 - 8 درجات مئوية). احتفظ بوجود حاوية العقار داخل علبته الكرتونية الخارجية لحمايته من الضوء. لا تقم بتجميده.</p><p dir="RTL">يمكن الاحتفاظ بالمنتج خارج الثلاجة لفترة لا تتجاوز ثلاثة أشهر (دون أن يتعدى المنتج تاريخ الانتهاء)، مع تخزينه في درجة حرارة أقل من 25 درجة مئوية. بنهاية هذه الفترة، لا يمكن الاحتفاظ بالمنتج داخل الثلاجة مع وجوب التخلص منه. يجب تسجيل التاريخ الذي تم فيه خروج المنتج من الثلاجة على العلبة الكرتونية الخارجية.</p><p dir="RTL">لا تستخدم أوكتاجام 10<strong>%</strong> إذا لاحظت تعكر المحلول، أو انتبهت لاحتوائه على رواسب، أو تغير لونه بشكل جذري.</p><p dir="RTL">لا ينبغي التخلص من الأدوية في مياه الصرف الصحي أو المخلفات المنزلية. استفسر من الصيدلي عن كيفية التخلص من الأدوية إذا لم تعد بحاجة إليها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي الجلوبيولين المناعي الطبيعي للإنسان &nbsp;10<strong>% </strong>(على الأقل نسبة 95% من العقار تتمثل في الجلوبيولين المناعي G).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بينما تتمثل المكونات الأخرى في المالتوز والمياه اللازمة للحُقَن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أوكتاجام 10<strong>% </strong>عبارة عن محلول تقطير، متوفر في قارورة (2 جم/20 ملم)، أو زجاجات (5 جم/50 ملم، 10 جم/100 ملم، 20 جم/200 ملم). حجم العبوة الواحدة.</p><p dir="RTL">يكون المحلول نقيًا، أو غميمًا بعض الشيء، بلا أي لون أو يميل إلى الصفرة.</p><p dir="RTL"><strong>قد</strong> لا تتوفر بعض أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اوكتافارنا ايه جي</p><p dir="RTL">سايدينستراس 2</p><p dir="RTL">8853 لاشين</p><p dir="RTL">سويسرا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنّعين</strong></p><p dir="RTL">اوكتافارما فارماسوتيكا برودكشنجيس ام بي اتش</p><p dir="RTL">اوبيرلار ستراس 235، 1100 فينا، النمسا</p><p dir="RTL">&nbsp;</p><p dir="RTL">اوكتافارما ايه بي</p><p dir="RTL">لارس فورسيلز غاتا 23، 11275 ستوكهولم، السويد</p><p dir="RTL">&nbsp;</p><p dir="RTL">اوكتافارم &nbsp;ساس</p><p dir="RTL">ريو دي مارشيل ,<em> </em><em>BP 33, F-6738</em><strong><em>,لينغوشليم, فرنسا </em></strong><em>70-72-</em></p><p dir="RTL"><strong>هاتف رقم: </strong>&nbsp;+ 33 3&nbsp; 88 78 89 89</p><p dir="RTL">فاكس رقم: &nbsp;+ 33 3 88 78 89 78</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2023 م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OCTAGAM 10%, solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Human normal immunoglobulin (IVIg)*   100 mg/ml
* corresponding to the total protein content of which at least 95% is human Immunoglobulin G

Distribution of IgG subclasses:
IgG1		ca. 60%
IgG2		ca. 32%
IgG3		ca. 7%
IgG4		ca. 1%
Maximum IgA content: 0.4 mg

One vial of 20 ml contains 2g of human normal immunoglobulin.
One vial of 50 ml contains 5g of human normal immunoglobulin.
One vial of 100 ml contains 10g of human normal immunoglobulin.
One vial of 200 ml contains 20g of human normal immunoglobulin.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
The liquid preparation is clear to slightly opalescent and colourless to slightly yellow. The pH of the liquid preparation is 4.5 – 5.0, the osmolality is ≥ 240 mosmol/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replacement therapy in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary immunodeficiency syndromes such as:<br />- congenital agammaglobulinaemia and hypogammaglobulinaemia<br />- common variable immunodeficiency<br />- severe combined immunodeficiency<br />- Wiskott Aldrich syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children with congenital AIDS and recurrent infections.</p><p>4.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immunomodulation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Idiopathic thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guillain Barr&eacute; syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kawasaki disease</p><p>4.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allogeneic bone marrow transplantation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Posology</p><p>The dose and dosage regimen is dependent on the indication.</p><p>In replacement therapy the dosage may need to be individualised for each patient dependent on the pharmacokinetic and clinical response.</p><p>The following dosage regimens are given as a guideline:</p><p><u>Replacement therapy in primary immunodeficiency syndromes</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dosage regimen should achieve a trough level of IgG (measured before the next infusion) of at least 4 &ndash; 6 g/l. Three to six months are required after the initiation of therapy for equilibration to occur. The recommended starting dose is 0.4 - 0.8 g/kg, followed by at least 0.2 g/kg every three weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose required to achieve a trough level of 6 g/l is of the order of 0.2 - 0.8 g/kg/month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dosage interval when steady state has been reached, varies from 2 to 4 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trough levels should be measured in order to adjust the dose and dosage interval.</p><p><u>Replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; replacement therapy in children with AIDS and recurrent infections:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 0.2 - 0.4 g/kg every three to four weeks.</p><p><u>Idiopathic Thrombocytopenic Purpura:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of an acute episode, 0.8 - 1 g/kg on day one, which may be repeated once within 3 days, or 0.4 g/kg daily for two to five days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The treatment can be repeated if relapse occurs.</p><p><u>Guillain Barr&eacute; syndrome:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.4 g/kg/day for 3 to 7 days. Experience in children is limited.</p><p><u>Kawasaki disease:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.6 - 2 g/kg should be administered in divided doses over two to five days or 2 g/kg as a single dose. Patients should receive concomitant treatment with acetylsalicylic acid.</p><p><u>Allogeneic Bone Marrow Transplantation:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Human normal immunoglobulin treatment can be used as part of the conditioning regimen and after the transplant. For the treatment of infections and prophylaxis of graft versus host disease, dosage is individually tailored.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is normally 0.5 g/kg/week, starting seven days before transplantation and for up to 3 months after transplantation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the case of persistent lack of antibody production, dosage of 0.5 g/kg/month is recommended until antibody level returns to normal.</p><p>The dosage recommendations are summarised in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p>Indication</p></td><td><p>Dose</p></td><td><p>Frequency of injection</p></td></tr></thead><tbody><tr><td><p>Replacement therapy in primary immunodeficiency</p><p>&nbsp;</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; Starting dose:<br />0.4 - 0.8 g/kg</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Thereafter:<br />0.2 - 0.8 g/kg</p></td><td><p><br />&nbsp;</p><p>every 2 - 4 weeks to obtain IgG trough level of at least 4 - 6 g/l</p><p>&nbsp;</p></td></tr><tr><td><p>Replacement therapy in secondary immunodeficiency</p><p>&nbsp;</p><p>Children with AIDS</p></td><td><p>0.2 - 0.4 g/kg</p><p>&nbsp;</p><p><br />0.2 &ndash; 0.4 g/kg</p></td><td><p>every 3 - 4 weeks to obtain IgG trough level of at least 4 - 6 g/l<br /><br /><br />every 3 - 4 weeks</p></td></tr><tr><td><p>Immunomodulation:</p><p>Idiopathic Thrombocytopenic Purpura</p></td><td><p>&nbsp;</p><p>0.8 - 1 g/kg<br />or<br />&nbsp;</p><p>0.4 g/kg/day</p></td><td><p>&nbsp;</p><p>on day 1, possibly repeated once within 3 days<br />&nbsp;</p><p>for 2-5 days<br />&nbsp;</p></td></tr><tr><td><p>Guillain Barr&eacute; syndrome</p></td><td><p>0.4 g/kg/day</p></td><td><p>for 3-7 days<br />&nbsp;</p></td></tr><tr><td><p>Kawasaki syndrome</p></td><td><p>1.6 - 2 g/kg</p><p>or</p></td><td><p>in several doses for 2 - 5 days in association with acetylsalicylic acid</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>2 g/kg</p></td><td><p>in one dose in association with acetylsalicylic acid</p></td></tr><tr><td><p>Allogeneic bone marrow transplantation:</p><p>-&nbsp; treatment of infections and prophylaxis of graft versus host disease</p></td><td><p><br />&nbsp;</p><p>0.5 g/kg</p></td><td><p><br />&nbsp;</p><p>every week from day -7 up to 3 months after transplantation</p></td></tr><tr><td><p>-&nbsp; Persistent lack of antibody production</p></td><td><p>0.5 g/kg</p></td><td><p>every month until IgG levels return to normal</p></td></tr></tbody></table><p>&nbsp;</p><p>4.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Method of administration</p><p>Octagam 10% should be infused intravenously at an initial rate of 0.01 mL/kg body weight per minute for 30 minutes. If well tolerated, the rate of administration may gradually be increased to a maximum of 0.12 mL/kg/ body weight per minute.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients of Octagam 10% .
Hypersensitivity to homologous immunoglobulins, especially in the very rare cases of IgA deficiency when the patient has antibodies against IgA.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Certain severe adverse drug reactions may be related to the rate of infusion. The recommended infusion rate given under &ldquo;4.2 Method of administration&quot; must be closely followed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.</p><p>Certain adverse reactions may occur more frequently:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of high rate of infusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with hypo- or agammaglobulinaemia, with or without IgA deficiency</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion</p><p>True hypersensitivity reactions are rare. They can occur in very seldom cases of IgA deficiency with anti-IgA antibodies.</p><p>Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin.</p><p>Potential complications can often be avoided by ensuring:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that patients are not sensitive to human normal immunoglobulin by initially injecting the product slowly (0.01 to 0.02 mL/kg body weight per minute);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that patients are carefully monitored for any symptoms throughout the infusion period; in particular, patients naive to human normal immunoglobulin, patients switched from an alternative IVIg product to Octagam 10% or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs. All other patients should be observed for at least 20 minutes after administration.</p><p>There is clinical evidence of an association between IVIg administration and thromboembolic events such as myocardial infarction, stroke, pulmonary embolism and deep vein thromboses which is assumed to be related to a relative increase in blood viscosity through the high influx of immunoglobulin in at-risk patients. Caution should be exercised in prescribing and infusing IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, patients with diseases which increase blood viscosity).</p><p>Cases of acute renal failure have been reported in patients receiving IVIg therapy. In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolemia, overweight, concomitant nephrotoxic medicinal products or age over 65.</p><p>In case of renal impairment, IVIg discontinuation should be considered. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IVIg products containing various excipients such as sucrose, glucose and maltose, those containing sucrose as a stabiliser accounted for a disproportionate share of the total number. In patients at risk, the use of IVIg products not containing such excipients may be considered.</p><p>In patients at risk for acute renal failure or thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.</p><p>In all patients, IVIg administration requires:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adequate hydration prior to the infusion of IVIg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monitoring of urine output</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monitoring of serum creatinine levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avoidance of concomitant use of loop diuretics</p><p>In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped. The treatment required depends on the nature and severity of the side effect.</p><p>In case of shock, standard medical treatment for shock should be implemented.</p><p>Some types of blood glucose testing systems may falsely interpret the maltose (90 mg/ml) contained in Octagam 10% as glucose. This may result in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin and cases of true hypoglycaemia may go untreated if the hypoglycaemic state is masked by falsely elevated glucose readings. For further details see Section 4.5.</p><p>Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.</p><p>The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV.</p><p>The measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.</p><p>There is a reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.</p><p>It is strongly recommended that every time that Octagam 10% is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In order to infuse any product that may remain in the infusion tubing at the end of the infusion the tubing may be flushed with either 0.9% saline or 5% dextrose solution.</p><p><u>Live attenuated virus vaccines</u></p><p>Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year. Therefore, patients receiving measles vaccine should have their antibody status checked.</p><p><u>Interference with serological testing</u></p><p>After injection of immunoglobulin the transitory rise of various passively transferred antibodies in the patients blood may result in misleading positive results in serological testing.</p><p>Passive transmission of antibodies to erythrocyte antigens, e.g. A, B or D may interfere with some serological tests for red cell allo-antibodies, for example the antiglobulin test (e.g. Coombs Test).</p><p><u>Blood Glucose Testing</u></p><p>Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods) falsely interpret the maltose (90 mg/ml) contained in Octagam 10% as glucose. This may result in falsely elevated glucose readings <strong>during an infusion and</strong> for a period of about 15 hours after the end of the infusion and, consequently, in the inappropriate administration of insulin, resulting in life-threatening or even fatal hypoglycemia. Also, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Accordingly, when administering Octagam 10% or other parenteral maltose- containing products, the measurement of blood glucose must be done with a glucose-specific method.</p><p>The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose- containing parenteral products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected. Immunoglobulins are excreted into the milk and may contribute to the transfer of protective antibodies to the neonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effects on ability to drive and use machines have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In general, various allergic and hypersensitivity type of reactions and headache, chills, back pain, chest pain, fever, cutaneous reactions, vomiting, arthralgia, low blood pressure and nausea may occasionally occur. Reactions to intravenous immunoglobulins tend to be related to the dose and the rate of infusion.</p><p>The frequencies given in the following table are derived from clinical studies that were conducted with Octagam 5% (columns named &quot;common&quot; and &quot;uncommon&quot;) and from postmarketing experience with Octagam 5% (column named &quot;very rare&quot;). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA 8.1 Coded</strong></p></td><td style="vertical-align:top"><p><strong>Common<br /><u>&gt;</u>1% - &lt;10%</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon<br /><u>&gt;</u>0.1% - &lt;1%</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare<br />&lt; 0.01%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>leukopenia;<br />haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactic shock;<br />anaphylactic reaction;<br />anaphylactoid reaction;<br />angioneurotic oedema;<br />face oedema</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>agitation</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cerebrovascular accident;<br />meningitis aseptic;<br />migraine;<br />dizziness;<br />paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>myocardial infarction;<br />tachycardia;<br />palpitations;<br />cyanosis</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>thrombosis;<br />peripheral circulatory failure;<br />hypotension;<br />hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>respiratory failure;<br />pulmonary embolism;<br />pulmonary oedema;<br />bronchospasm;<br />dyspnoea;<br />cough</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vomiting;<br />diarrhoea;<br />abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eczema;</p></td><td style="vertical-align:top"><p>urticaria;<br />rash;<br />rash erythematous;<br />dermatitis;<br />pruritus;<br />alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>back pain</p></td><td style="vertical-align:top"><p>arthralgia;<br />myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>renal failure acute</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>fever;<br />fatigue;<br />injection site reaction</p></td><td style="vertical-align:top"><p>chills;<br />chest pain</p></td><td style="vertical-align:top"><p>hot flush;<br />flushing;<br />hyperhidrosis;<br />malaise</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatic enzymes increased;<br />blood glucose false positive</p></td></tr></tbody></table><p>&nbsp;</p><p>Cases of reversible aseptic meningitis, isolated cases of reversible haemolytic anaemia/haemolysis and rare cases of transient cutaneous reactions, have been observed with human normal immunoglobulin.</p><p>Increase in serum creatinine level and/or acute renal failure have been observed.</p><p>Very rarely: Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses.</p><p>Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.</p><p>Standard measures are taken to prevent infections resulting from the use of medicinal products prepared from human blood or plasma. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens. For safety with respect to transmissible agents, see 4.4.</p><p>Clinical experience in children is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose may lead to fluid overload and hyperviscosity, particularly in patients at risk, including elderly patients or patients with renal impairment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration,</p><p>ATC-Code: J06B A02</p><p>Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents.</p><p>Human normal immunoglobulin contains the IgG antibodies present in the normal population.</p><p>It is prepared from pooled plasma from not fewer than 1000 donations. It has a distribution of immunoglobulin G-subclasses closely proportional to that in native human plasma. Adequate doses of this medicinal product may restore abnormally low Immunoglobulin G level to the normal range.</p><p>The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.</p><p><u>&nbsp;</u></p><p><u>Clinical Studies</u></p><p>In a prospective, open-label, multicentre phase III trial, the efficacy and safety of Octagam 10% was studied in patients suffering from idiopathic (immune) thrombocytopenic purpura (ITP). Octagam 10% was infused on 2 consecutive days at a dose of 1 gram/kg/day, and patients were observed for a period of 21 days and at a follow-up visit on Day 63 post-infusion. Haematology parameters were assessed on Days 2 to 7, 14 and 21.</p><p>A total of 31 subjects were included in the analysis; 15 were subjects with chronic ITP, 15 were newly-diagnosed, and 1 subject was incorrectly enrolled in the study (had no ITP) and was therefore excluded from the efficacy analysis.</p><p>In total, 25 subjects (83%) showed a clinical response. A higher clinical response rate was seen in the newly-diagnosed cohort (93%) than in the chronic ITP cohort (73%). In subjects with a response, the median time to platelet response was 2 days, with a range of 1 to 5 days.</p><p>In 24 subjects (77%), Octagam 10% was given at the maximum allowed infusion rate of 0.06&nbsp;mL/kg/min. Following a Protocol Amendment, 2 patients of the presented analysis received the product at a rate of 0.08&nbsp;mL/kg/min which was uneventful in both cases. In the continuation of this on-going study, 22 subjects have been treated with the maximum allowed infusion rate of 0.12 mL/kg/min.</p><p>In 9 of 62 infusions (14.5%) treatment-related infusional AE were observed. The most common drug-related AE was headache, followed by tachycardia and pyrexia. There was no case of haemolysis related to the study drug. Pre-treatment to alleviate infusion-related intolerability was not given.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human normal immunoglobulin is immediately and completely bioavailable in the recipient&rsquo;s circulation after intravenous administration. It is distributed relatively rapidly between plasma and extravascular fluid, after approximately 3-5 days equilibrium is reached between the intra- and extravascular compartments.</p><p>Human normal immunoglobulin has an average half life ranging from 26 to 41 days, as measured in immunodeficient patients. This half-life may vary from patient to patient, in particular in primary immunodeficiency.<em> </em>For Octagam 10%, no formal pharmacokinetic data in immunodeficient patients have been obtained.</p><p>IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immunoglobulins are normal constituents of the human body. Studies of repeated dose toxicity, genotoxicity, and toxicity to reproduction in animals are impracticable due to induction of and interference by developing antibodies to heterologous proteins. Since clinical experience provides no evidence for carcinogenic or mutagenic potential of immunoglobulins, no experimental studies in heterogolous species were performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maltose&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>Keep the container in the outer carton in order to protect from light.</p><p>The product may be removed from the refrigerator for a single period of up to 3 months (without exceeding the expiry date) and stored at a temperature below 25&deg;C. At the end of this period, the product should not be refrigerated again and should be disposed of. The date at which the product was taken out of the refrigerator should be recorded on the outer carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20 ml of solution in a 30 ml vial (type II glass) with a stopper (bromobutyl rubber).</p><p>50 ml of solution in a 70 ml bottle (type II glass) with a stopper (bromobutyl rubber).</p><p>100 ml of solution in a 100 ml bottle (type II glass) with a stopper (bromobutyl rubber).</p><p>200 ml of solution in a 250 ml bottle (type II glass) with a stopper (bromobutyl rubber).</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product should be brought to room or body temperature before use.</p><p>The solution should be clear to slightly opalescent and colourless to slightly yellow.</p><p>Do not use solutions that are cloudy or have deposits.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Due to the possibility of bacterial contamination, any remaining contents must be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Octapharma AG
Seidenstrasse 2
CH-8853 Lachen
Switzerland
Tel: +41 5545 121 0

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>